These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3667165)

  • 1. Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.
    Amato DA; Bruckner H; Guerry D; Ash A; Falkson G; Borden EC; Creech RH; Savlov ED; Cunningham TJ
    Invest New Drugs; 1987; 5(3):293-7. PubMed ID: 3667165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
    Samson MK; Haas CD; Baker LH; Cummings G
    Am J Clin Oncol; 1985 Apr; 8(2):167-71. PubMed ID: 3834791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
    Creagan ET; Ahmann DL; Schutt AJ; Green SJ
    Cancer Treat Rep; 1982 Jun; 66(6):1425-6. PubMed ID: 7083244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of dibromodulcitol and BCNU in metastatic malignant melanoma.
    Clamon G; Sinkey C; Jochimsen P
    Am J Clin Oncol; 1985 Jun; 8(3):244-6. PubMed ID: 4050743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
    Creagan ET; Schutt AJ; Long HJ; Green SJ
    Med Pediatr Oncol; 1986; 14(2):86-7. PubMed ID: 3713642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of dibromodulcitol (DBD) in stage IV melanoma.
    Hopkins J; Richards F; Case D; Pope E; Jackson DV; Stuart JJ; Muss HB; White DR; Cooper MR; Spurr CL
    Am J Clin Oncol; 1984 Oct; 7(5):555-6. PubMed ID: 6507378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitolactol chemotherapy for malignant melanoma: a phase II study.
    Malden LT; Coates AS; Milton GW; McCarthy WH; Levi JA; Woods RL; Byrne MJ; Reynolds PM; Fox RM; Hedley DW
    Cancer Treat Rep; 1984; 68(7-8):1045-6. PubMed ID: 6744338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dibromodulcitol-based combined postoperative chemotherapy of malignant astrocytomas and glioblastomas.
    Afra D; Kocsis B; Kerpel-Fronius S; Eckhardt S
    J Neurooncol; 1986; 4(1):65-70. PubMed ID: 3746387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas.
    Afra D; Kocsis B; Dobay J; Eckhardt S
    J Neurosurg; 1983 Jul; 59(1):106-10. PubMed ID: 6306179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.
    Mulder NH; Sleijfer DT; Smit JM; De Vries EG; Willemse PH; Koops HS
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):879-81. PubMed ID: 2429842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of mitolactol in metastatic malignant melanoma.
    Simmonds MA; Lipton A; Harvey HA; Ellison N; White DS
    Cancer Treat Rep; 1985 Jan; 69(1):65-7. PubMed ID: 3967260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).
    Baker LH; Frank J; Fine G; Balcerzak SP; Stephens RL; Stuckey WJ; Rivkin S; Saiki J; Ward JH
    J Clin Oncol; 1987 Jun; 5(6):851-61. PubMed ID: 3295129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adults.
    Yap BS; Benjamin RS; Burgess MA; Murphy WK; Sinkovics JG; Bodey GP
    Cancer; 1981 Jun; 47(12):2807-9. PubMed ID: 7260872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of vinblastine, bleomycin, and cisplatin induction followed by dacarbazine and dibromodulcitol maintenance in the treatment of metastatic melanoma. A follow-up study of twenty-two patients.
    Gentile PS; Epremian BE; Seeger J; Hamm JT; Sheth SP
    Am J Clin Oncol; 1988 Dec; 11(6):666-8. PubMed ID: 2461074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
    Costanzi JJ; Fletcher WS; Balcerzak SP; Taylor S; Eyre HJ; O'Bryan RM; Al-Sarraf M; Frank J
    Cancer; 1984 Feb; 53(4):833-6. PubMed ID: 6362830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results with methyl-CCNU and DTIC in metastatic melanoma.
    Costanza ME; Nathanson L; Schoenfeld D; Wolter J; Colsky J; Regelson W; Cunningham T; Sedransk N
    Cancer; 1977 Sep; 40(3):1010-5. PubMed ID: 332319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea.
    Bellet RE; Catalano RB; Mastrangelo MJ; Berd D
    Cancer Treat Rep; 1978 Dec; 62(12):2095-9. PubMed ID: 751717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Stehman FB; Blessing JA; McGehee R; Barrett RJ
    J Clin Oncol; 1989 Dec; 7(12):1892-5. PubMed ID: 2685182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma.
    Ahmann DL; Hahn RG; Bisel HF; Eagan RT; Edmonson JH
    Cancer Chemother Rep; 1975; 59(2 Pt 1):451-3. PubMed ID: 1097102
    [No Abstract]   [Full Text] [Related]  

  • 20. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study.
    Curry SL; Blessing JA; DiSaia PJ; Soper JT; Twiggs LB
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):357-62. PubMed ID: 2536911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.